TABLE 3.
Disease associations and specificities of peptide-stimulated IL-10 responses
| Peptide sequence | No. of IL-10 positivea/total no. of Indian subjects (%)
|
|||
|---|---|---|---|---|
| Healthy controls | TT/BT leprosy | LL/BL leprosy | Total | |
| 41–55 | 1/7 | 1/10 | 1/7 | 3/24 (12.5) |
| 141–155 | 0/7 | 2/10 | 2/7 | 4/24 (16.7) |
| 206–220 | 0/6 | 0/10 | 2/7 | 2/23 (8.7) |
| 231–245 | 1/7 | 1/9 | 4/7 | 6/23 (26.1) |
| 241–255 | 3/7 | 3/9 | 4/7 | 10/23c (43.5) |
| Total | 5/34 (14.7) | 7/48 (14.6) | 13/35b (37.1) | |
a
Cutoff: increment of >100 pg/ml and at least twice above background (no peptide) value.
b
Higher than either controls or TT/LL patients (P < 0.01; Fisher’s exact test).
c
Higher than 41–55, 141–155, or 231–245 (P < 0.01; Fisher’s exact test).